HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 279, Issue 51, 53116-53125, December 17, 2004

This Article Abstract Full Text (PDF) All Versions of this Article: 279/51/53116    most recent M405502200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, Y. Articles by Kraft, A. S. Search for Related Content PubMed PubMed Citation Articles by Zhang, Y. Articles by Kraft, A. S. Social Bookmarking                      What's this?

Phorbol Ester Treatment of K562 Cells Regulates the Transcriptional Activity of AML1c through Phosphorylation^*

Youhong Zhang, Joseph R. Biggs, and Andrew S. Kraft

From the Hollings Cancer Center, the Medical University of South Carolina, Charleston, South Carolina 29425

Received for publication, May 17, 2004 , and in revised form, September 30, 2004.

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
We find that phorbol ester (PE) treatment of K562 cells greatly stimulates promoters (T cell receptor , myeloperoxidase, macrophage colony-stimulating factor receptor, and granulocyte macrophage colony-stimulating factor receptor) containing AML1 transcription factor binding sites. This stimulation of AML1c transcriptional activity is mediated by direct phosphorylation of the AML1c molecule on multiple phosphorylation sites. Eleven AML1c (S/T)P sites in the transcriptional activating domain are phosphorylated at a basal level in untreated K562 cells; treatment of the K562 cells with PE results in increased phosphorylation at five of these sites (serines 276, 293, 303, 462, and threonine 300). Mutation of these five sites to alanine inhibits PE-induced transcriptional activity; mutation of the sites to an acidic amino acid, aspartic acid, stimulates constitutive activity. Single mutations in four amino acids or double mutations (serines 276 and 293 or threonine 300 and serine 303) have little effect on AML1c transcriptional activity. Inhibitor assays suggest that the ERK family of protein kinases is activated by PEs to phosphorylate the (S/T)P sites within the AML1c molecule and markedly enhance the transcriptional activity of AML1c.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Treatment of hematopoietic cells with phorbol esters, such as phorbol 12-myristate 13-acetate (PMA),¹ causes them to undergo differentiation to more mature cell types. The U937, HL-60, NB-4, and PBL leukemic cell lines differentiate into monocyte-like cells, whereas the K562 cell line differentiates into megakaryocyte-like cells (reviewed in Ref. 1). The ability of phorbol esters to induce differentiation of leukemic cells has suggested that additional compounds that activate protein kinase C might be used as treatments for human leukemia (2). It is possible that PMA-induced differentiation occurs through the regulation of a limited number of key proteins, for example transcription factors, that are essential for hematopoiesis. The AML1 transcription factor is necessary for definitive hematopoiesis in embryonic stem cells (3) and for commitment to the hemangioblast stage of development (4). AML1 proteins, including AML1a, AML1b, and AML1c (AML1c is also known as AML1B), are generated from one gene by alternative splicing (5). The AML1c protein is composed of a DNA binding domain (also know as the runt domain) located in the amino terminus of the molecule (amino acids 85–204 in AML1c) and a transcriptional activating domain that occupies a significant portion of the carboxyl terminus. The runt domain of the AML1 proteins dimerizes with core binding factor (CBF), and together they bind a specific DNA sequence and play a critical role in regulating definitive hematopoiesis (6). Mice that contain a homozygous knock-out for AML1 or CBF are embryonic lethal (7) with absent hematopoiesis and hemorrhage in the central nervous system. The importance of AML1 to normal hematopoietic development is further identified by the frequent disruption of AML1 secondary to translocations (AML/ETO, AML/EVI1, and TEL/AML), deletions, or point mutations (8) in more than 30% of human leukemias. Mutations that destroy one of the AML1 alleles are associated with familial platelet disorders (9), demonstrating that a specific level of AML1 expression is required for normal hematopoiesis. AML1 proteins regulate the transcription of a number of important hematopoietic genes including the T cell receptor and (TCR,), granulocyte macrophage colony-stimulating factor, myeloperoxidase and neutrophil elastase proteins, and colony-stimulating factor-1 receptor (10–14). Transfection of AML1 leukemic fusions into hematopoietic cells inhibits differentiation and enhances progenitor cell self-renewal (15). Thus, AML1 is a protein that plays a critical role in the control of hematopoietic differentiation.

Evidence suggests the possibility that PMA-induced differentiation of hematopoietic cells could in part be regulated by stimulation of the transcription factor AML1. First, this differentiation program is associated with increases in transcription of mRNAs, e.g. CSF-1 receptor, myeloperoxidase, and elastase that are similarly regulated by AML1 (16–18). Second, transfection of U937 cells with the dominant repressor protein AML/ETO, a leukemic fusion, blocks the ability of PMA to induce differentiation of these cells (19), suggesting that AML1 activity is necessary for the differentiation process. Third, the knock down of AML/ETO in the human leukemic cell line Kasumi sensitizes these cells to PMA-induced differentiation (20). Thus, the control of AML1 activity by PMA could be essential to the induction of differentiation.

The activity of AML1 appears to be controlled by multiple transcriptional activators and repressors. This protein has been shown to bind to the histone acetylases, p300, MOZ, and MORF, and to the transcriptional activator HES-1 (13, 21–23). The YAP coactivator, which contains a WW protein interaction domain, interacts with a specific PY domain in the carboxylterminal half of the AML1 protein (24). The corepressor groucho/transducin-like enhancer of split (Gro/TLE) interacts with the carboxyl-terminal VWRPY amino acid sequence, and transcriptional repressors mSin3 and N-Cor interact with the AML1 and with histone deacetylases (12, 25). AML1 interacts with other DNA binding factors. It can bind to the ETS family of transcription factors in vitro, and it can synergize and interact with PU.1, another ETS family member in vivo to activate the macrophage colony-stimulating factor promoter (26). Interaction with this ETS factor along with ALY, ATF/CREB, and LEF1 proteins is crucial for the stimulation of the T cell receptor gene. Another potential mechanism for regulation of AML1 activity is its interaction with the nuclear matrix. Extraction of nuclei with detergent and high salt followed by treatment with nucleases failed to remove AML1 from the matrix, and immunostaining indicated that this protein is found in specific dot-like structures in the nucleus (27). Finally, human AML1 has been shown to be a phosphoprotein, and the level of phosphorylation of this protein can be controlled by the addition of interleukin 3 to hematopoietic cells. The phosphorylation of AML1 can be stimulated by the addition of epidermal growth factor to COS-7 cells transfected with the receptor for this protein. In these cells AML1 appears to physically bind to the ERK protein kinase (28).

Phorbol ester treatment has been shown to activate several kinase pathways in leukemic cells (29) including the protein kinase C cascade, which in hematopoietic cells leads to the activation of all three members of the mitogen-activated protein kinase family of enzymes (ERK, c-Jun NH₂-terminal kinase, and p38). These protein kinases induce the phosphorylation and activation of multiple types of transcription factor, including c-JUN (30), NF-B (31), and the ETS family members ETS-1 (32), ETS-2 (33), PU.1 (34), ERG-2 (35), and ELF-1 (29). Regulation of a number of these transcription factors is essential for PMA-induced hematopoietic differentiation (34). Because AML1 is a known phosphoprotein (28), the possibility that AML1 could be targeted by PMA-induced protein kinases was investigated.

By using K562 cells as a model system, we find that PMA-induced differentiation stimulates the activation of AML1-containing promoters. Activation of AML1 is mediated by PMA-induced phosphorylation of specific serine/threonine residues within the carboxyl terminus of this molecule.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Cell Culture and Transfection—K562 cells were grown in RPMI medium supplemented with 10% bovine calf serum at 37 °C in 5% CO_2. For transfection, 2 x 10⁶ K562 cells were suspended in 0.8 ml of PBS with DNA and transferred to a cuvette for electroporation. When MEK inhibitors were used, K562 cells were pretreated 1 h with either PD98059 or U0126 (Calbiochem) and then treated with 200 nM PMA (Calbiochem).

Plasmids—The pCMV-AML1c wild type expression plasmid was a gift from S. Hiebert (Vanderbilt University). The T cell receptor luciferase reporter plasmids were a gift from Y. Groner (Weizmann Institute) and the 4X-AML1 luciferase reporter plasmids were a gift from A. D. Friedman (The Johns Hopkins University). The chicken -actin promoter expression plasmid (pCAGIPuro) was a gift from Dr. H. Niwa (Osaka University). To make the GAL4-AML1c fusion protein, AML1c coding regions were amplified by PCR using primers containing BglII (5') and XbaI (3') sites; the resulting PCR products were cloned into the BamHI and XbaI sites of the GAL4 vector pSG424. The GAL4-AML1c coding sequence was then transferred to the pMEP expression vector (Invitrogen, discontinued). To mutate AML1c serine or threonine residues to alanine, overlapping primers containing the desired mutations were synthesized. The pCMV-Renilla-luciferase plasmid was purchased from Promega.

Protein Fractions and Western Blots—To examine total cell proteins, K562 cells were pelleted, washed in PBS, and boiled in 1x SDS sample buffer. To separate soluble proteins from nuclear matrix-associated proteins, cells were lysed in 0.5% IGEPAL-CA630 (similar to Nonidet P-40), 50 mM Tris, pH 7.5, 150 mM NaCl, 20 mM EDTA, 20 mM NaF, 1 mM vanadate, 10 mM benzamidine, 40 mM -glycerol phosphate, and protease inhibitors for 30 min at 4 °C. Insoluble proteins, including the nuclear matrix, were pelleted by spinning for 10 min in a microcentrifuge at 4 °C, and the soluble protein supernatant was drawn off. The insoluble pellet was washed once with PBS, then both soluble and insoluble fractions were then prepared for Western blot analysis by the addition of an equal volume of 2x SDS buffer (20% glycerol, 4% SDS, 100 mM Tris-HCl, pH 6.8, and 200 mM dithiothreitol) and heating at 100 °C for 5 min. Western blots themselves were performed as described previously (36). Anti-AML1 antibodies were purchased from Active Motif and Oncogene Research Products.

Luciferase Assays—Luciferase assays were carried out as described previously (36). For luciferase assays using K562 lysate, a small amount of pCMV-Renilla-luciferase plasmid was added to the AML1c expression plasmid and the 4X-AML1 luciferase or other reporter plasmid. A separate small portion of lysate was then assayed for Renilla luciferase activity by using a kit from Promega to normalize the 4X-AML1 luciferase values.

Immunoprecipitation of ³²P-Labeled Proteins—K562 cells transfected with expression vectors for FLAG-tagged AML1c proteins were incubated 5 h in medium containing 200 µCi/ml [³²P]orthophosphate. For immunoprecipitation, 10 µl of anti-FLAG-M2 agarose (Sigma) was added to each sample, followed by an overnight incubation on a rocker at 4 °C. Immunoprecipitates were then washed three times in lysis buffer, followed by heating at 100 °C for 5 min in SDS buffer for SDS-PAGE.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Phorbol Esters Stimulate AML1 Activity during K562-induced Differentiation—To examine the ability of PMA to regulate the activity of AML1, we transfected K562 cells with both the T cell receptor- (TCR-) promoter and an artificial promoter containing four multimerized AML1-binding sites preceding a minimal portion of the thymidine kinase promoter (37). PMA treatment of the transfected K562 cells resulted in a 50-fold increase in the activity of the TCR- promoter and an18-fold increase in the activity of the 4XAML1 promoter (Fig. 1A). In both cases, deletion of the AML1-binding sites markedly reduced the PMA induction observed. This result suggests that PMA induction of the TCR- and 4XAML1 promoters is mediated at least in part through the endogenous AML1 transcription factors expressed in K562 cells.

View larger version (19K): [in this window] [in a new window]   FIG. 1. Transcriptional activation by AML1c is stimulated by PMA and blocked by MEK inhibitors. A, plasmids containing either the wild type TCR- promoter or a promoter with mutated AML1-binding sites was transfected into K562 cells. Transfected cells were divided into two samples, and one sample was treated with 200 nM PMA. After 16 h, the samples were lysed and assayed for luciferase activity. Solid bars indicate activity in untreated samples; open bars indicate activity in PMA-treated samples. The same experiment was performed with either the 4XAML1 reporter plasmid or plasmid with the AML1-binding sites deleted. The plasmid used is indicated above the graphs, and both reporters are diagrammed at top. All experiments were repeated a minimum of five times, and the S.D. from the mean is shown. B, diagrams of the AML1c and GAL4-AML1c proteins are shown at top. K562 cells were transfected with 10 µg of GAL4-luciferase reporter and 20 µg of either empty vector (pMEP) or pMEP-GAL4-AML1c expression vector as indicated below each set of bars. Approximately 6 h after transfection, cells were treated with 1 µM CdSO4. After a further 2 h, cells were either treated with 200 nM PMA or left untreated (solid bars = CdSO4 only, open bars = CdSO4 + PMA). Sixteen to twenty four hours after transfection, cells were lysed for luciferase assays. All experiments were repeated a minimum of five times and the S.D. from the mean is shown. C, K562 cells were transfected with the TCR--luciferase reporter plasmid or the 4XAML1 luciferase reporterplasmid, as indicated above the two left-hand graphs. The transfected K562 samples were either pretreated with MEK inhibitors (PD98059 or U0126) or left untreated, as indicated below the graphs. One hour after treatment with inhibitors, samples were treated with PMA as indicated below the graphs. Samples were then incubated for 16 h before lysis for luciferase activity assays. The right-hand graph shows the reduction of GAL4-AML1c activity by MEK inhibitors. K562 cells were transfected with pMEP-GAL4-AML1c wild type expression plasmid and GAL4-luciferase reporter plasmid. Six hours after transfection, all samples were treated with CdSO4 to induce expression of GAL4-AML1c, and some samples were treated with MEK inhibitors, as indicated below the graph. One hour later, samples were treated with PMA or left untreated, as shown below the graph. After incubation for a further 16 h, samples were lysed for luciferase assays. All experiments were repeated a minimum of five times and the S.D. from the mean is shown.

To confirm that the biologic effects of PMA on AML1c regulation of the TCR- and 4XAML1 promoters involve the transactivation and not the DNA binding domain of AML1, a GAL4-AML1c fusion protein containing AML1c amino acids 201–480 (encoding only the transactivation domain) was constructed and placed in the pMEP expression plasmid (Fig. 1B). The pMEP plasmid drives expression through the metallothionein promoter, which can be induced by treating cells with zinc or cadmium. Unlike the cytomegalovirus promoter, the metallothionein promoter is not stimulated by PMA treatment, so PMA treatment does not affect the level of protein expressed with the pMEP plasmid. To measure the activity of the GAL4-AML1c protein, the expression plasmid was cotransfected into K562 cells with a GAL4-luciferase reporter plasmid (containing promoter-binding sites for the GAL4 protein). Transfected cells were then divided into two samples, one treated with CdSO₄ alone to induce expression of the GAL4-AML1c protein and the other treated with CdSO₄ and PMA. As shown in Fig. 1B, the carboxyl terminus of AML1c contains a PMA-responsive activation domain.

PMA treatment of K562 cells activates the ERK kinase pathway, as well as other protein kinases (29). Because the ERK kinase have been shown to bind and phosphorylate AML1 (28), and PMA activates these kinases, we examined the role of inhibitors of MEK in regulating PMA-induced activation of promoters containing AML1-binding sites. K562 cells were transfected with the TCR--luciferase reporter plasmid, the 4XAML1 luciferase reporter plasmid, or with the pMEP/GAL4-AML1c expression plasmid and GAL4-luciferase reporter plasmid (Fig. 1C) and either pretreated with MEK inhibitors (PD98059 or U0126) or left untreated. One hour after treatment with inhibitors, samples were treated with PMA and incubated for 16 h (pMEP/GAL4-AML1c samples were treated with CdSO₄ just before PMA addition) before lysis for luciferase activity assays. As shown in Fig. 1C, the MEK inhibitors block PMA activation of the AML1-binding site promoters and the GAL4-AML1c fusion protein. These results suggest that PMA-stimulated ERK phosphorylation of AML1c is required for PMA-induced activation of AML1c activity.

PMA Treatment of K562 Cells Stimulates the Phosphorylation of the AML1c Protein—The data shown in Fig. 1 suggest that PMA treatment of K562 cells may induce direct phosphorylation of the carboxyl terminus of AML1c. K562 cells clearly have sufficient endogenous AML1 protein to mediate PMA activation of promoters containing AML1-binding sites. However, the low level of endogenous AML1 makes interpretation of the Western blots somewhat difficult. To overcome these problems, K562 cells were stably transfected with the pMEP vector expressing AML1c under the control of the metallothionein promoter. As shown in Fig. 2A, treatment of this cell line with CdSO₄ induced high levels of AML1c expression that was expressed as a doublet band (not clearly separated) on SDS-polyacrylamide gels. After 15 min of treatment with PMA, a slower mobility form of AML1c appeared, creating a retarded band above the doublet, suggesting that PMA enhanced the phosphorylation of AML1c in K562 cells. This band was still visible 4 h after the start of PMA treatment, demonstrating this was a long-lived modification of this protein. Analysis of the lysates from these K562 cells with anti-phospho-ERK antibodies that identify activated ERK kinase revealed that some active ERK is present in untreated cells, but PMA treatment causes a substantial increase in ERK phosphorylation and activity. Consistent with this result, immunoprecipitation of AML1c from K562 cells labeled with [³²P]orthophosphate, but not treated with PMA, revealed that the AML1c in untreated cells is phosphorylated (Fig. 2B, lanes 1 and 2). PMA treatment appears to result in an increase in the level of AML1c phosphorylation beyond that observed in untreated cells. Pretreatment with the MEK inhibitor PD98059 reduced the level of AML1c phosphorylation in both untreated (Fig. 2C) and PMA-treated cells (Fig. 2B, compare lanes 3 and 4). Thus, base-line ERK activity in untreated K562 cells may be sufficient to partially phosphorylate AML1c, and PMA treatment enhances both ERK activity and AML1c phosphorylation.

View larger version (19K): [in this window] [in a new window]   FIG. 2. AML1c is phosphorylated in untreated K562 cells; PMA treatment induces further phosphorylation. A, K562 cells were stably transfected with the pMEP vector expressing AML1c under the control of the metallothionein promoter. Cells were treated with CdSO4 for 8 h to induce expression of AML1c and for various times with 200 nM PMA as indicated above the lanes. After treatment, cell samples were lysed for Western blotting with anti-AML1 antibodies. Lines to the right of A indicate the different forms of AML1c detected, a lower doublet (not well resolved) and an upper band enhanced by PMA treatment. B, K562/pMEP-AML1c cells were treated with CdSO4 to induce expression of AML1c. The AML1c proteins were then labeled by incubating the cells in media containing [32P]orthophosphate. After 3–4 h labeling with [32P]orthophosphate, some cell samples were pretreated with the MEK inhibitor PD98059 for 1 h and then treated an additional hour with PMA. Treatments are indicated above each lane. After treatment, the samples were lysed for immunoprecipitation. C, experiment was performed as in B, but without PMA treatment.

View larger version (39K): [in this window] [in a new window]   FIG. 3. PMA induces increased phosphorylation at 5 of 11 Ser-Pro or Thr-Pro sites in the AML1c activation domain. A, the diagram at top shows the location of the 3 Ser-Pro sites in the AML1c amino terminus and the 11 Ser-Pro or Thr-Pro sites in the activation domain. Below the diagram are 11 constructs containing AML1c amino acids 231–480 and one wild type Ser-Pro or Thr-Pro site. At the remaining 10 sites, each serine or threonine is mutated to alanine (x). The FLAG tag is indicated by the striped bar. B, each of the 11 constructs was transfected into K562 cells, which were then divided into two samples. Both samples were labeled with [32P]orthophosphate, and one was treated with 200 nM PMA with the other was left untreated. After treatment, the FLAG-tagged AML1c proteins were immunoprecipitated with anti-FLAG agarose and analyzed by autoradiography and Western blot. C, as in B, a construct containing the wild type threonine 300 and the remaining 10 serines or threonines mutated to alanine was transfected into K562 cells. Cells were treated as described in B.

To determine whether the Ser-Pro/Thr-Pro sites account for all AML1c activation domain phosphorylation, constructs with all 11 sites mutated, or just the 5 PMA-induced sites mutated, were compared with a wild type construct (diagrammed in Fig. 4A). As shown in Fig. 4B, mutation of the 11 Ser-Pro/Thr-Pro sites eliminates almost all phosphorylation. Mutation of the 5 sites (serines 276, 293, 303, 462, and threonine 300) eliminates PMA-induced phosphorylation.

View larger version (41K): [in this window] [in a new window]   FIG. 4. Mutation of 5 Ser-Pro/Thr-Pro sites eliminates PMA-induced AML1c phosphorylation, and mutation of 11 Ser-Pro/Thr-Pro sites eliminates most basal AML1c phosphorylation. A, the diagram at top shows the location of the 3 Ser-Pro sites in the AML1c amino terminus and the 11 Ser-Pro or Thr-Pro sites in the activation domain. Below the diagram are three constructs containing AML1c amino acids 231–480 and no Ser-Pro/Thr-Pro site mutations, 5 mutations, or 11 mutations, as shown. The FLAG tag is indicated by the small stripes at the amino terminus of the diagram. B, the three constructs were transfected into K562 cells and analyzed as in Fig. 3B.

View larger version (28K): [in this window] [in a new window]   FIG. 5. Effect of (S/T)P mutations on AML1c activity. A, the diagram at top shows the location of the 3 Ser-Pro sites in the AML1c amino terminus and the 11 Ser-Pro or Thr-Pro sites in the activation domain. Below the diagram are the full-length mutant AML1c proteins assayed for transcriptional activation. x indicates the location of serines or threonines mutated to alanine or aspartic acid (Ser Asp). B, K562 cells were transfected with 10 µg of 4X-AML1 luciferase reporter plasmid, 20 µg of empty vector (pcDNA3) or AML1c expression vector, and 0.25 µg of pCMV-Renilla-luciferase. The AML1c expression plasmids used are indicated below the graph. Approximately 6 h after transfection, cells were either treated with 200 nM PMA or left untreated (solid bars = untreated, and open bars = PMA). Sixteen to twenty four hours after transfection, cells were lysed for luciferase assays. Assays for luciferase activity from the 4X-AML1 luciferase plasmid (firefly luciferase) and for Renilla luciferase were carried out separately. The Renilla luciferase values were used to normalize the 4X-AML1 luciferase values. The values represent an average of at least three independent experiments, and the S.D. from the mean is shown. C, a diagram of wild type and mutant GAL4-AML1c fusion proteins is shown. Amino acids mutated from serine and threonine to alanine or aspartic acid are indicated for each construct. D, K562 cells were transfected with 10 µg of GAL4-luciferase reporter plasmid and 20 µg of either empty vector (pMEP) or pMEP-GAL4-AML1c expression vector. The GAL4-AML1c expression plasmid used is indicated below each set of bars. Approximately 6 h after transfection, cells were treated with 1 µM CdSO4. After a further 2 h, cells were either treated with 200 nM PMA or left untreated (solid bars = CdSO4 only, and open bars = CdSO4 + PMA). Sixteen to twenty four hours after transfection, cells were lysed for luciferase assays. All experiments were repeated a minimum of three times, and the S.D. from the mean is shown.

It is possible to mimic the effect of phosphorylation at serine or threonine residues by mutating the serine or threonine to glutamic acid or aspartic acid (38). This places a negative charge at the site is the same manner as the presence of phosphoserine or phosphothreonine. In AML1c-4M (Ser Asp), the four serines and threonines are mutated to aspartic acid. As shown in Fig. 5B when the cells are treated with PMA, this mutant AML1c protein has greater activity than wild type. This increase is clearly due to the placement of the charged amino acids at the four residues. We do not see a great deal of difference between the activity of AML1c-5M (Ser Asp) and AML1c-4M (Ser Asp) (Fig. 5B) treated with PMA. AML1c-5M (Ser Asp) contains the 4M (Ser Asp) mutations plus serine 462 mutated to aspartic acid.

We have observed that AML1c-11M has less transcriptional stimulatory activity on the 4X-AML1 promoter than AML1c-4M in K562 cells (Fig. 5B). This suggests the loss of basal phosphorylation at the remaining Ser-Pro or Thr-Pro sites has some effect on the function of this transcription factor.

As mentioned earlier, wild type or mutant AML1c expressed in K562 cells has to compete with endogenous AML1 proteins for the AML1-binding sites on the 4X-AML1 luciferase reporter, complicating the analysis of the mutant proteins (12). The endogenous protein induces background activity and ambiguity when full-length AML1c is assayed for activity in K562 cells. To avoid this problem, and to confirm results with full-length AML1c, we constructed the series of GAL4-AML1c fusion proteins with (S/T)P site mutations diagrammed in Fig. 5C. AML1c amino acids 201–480 (encoding the AML1c transactivation domain) were fused to the GAL4 DNA binding domain (GAL4 amino acids 1–147). The AML1c amino acid sequence was either wild type or carried some of the mutations analyzed in the previous section. DNA binding by the GAL4 domain will not be affected by mutations in the AML1c protein sequence. Therefore, the possibility that AML1c mutations affect activity by interfering with DNA binding is eliminated.

To compare the activity of the wild type and mutant GAL4-AML1c proteins, the expression plasmids were cotransfected into K562 cells with a GAL4-luciferase reporter plasmid (containing promoter-binding sites for the GAL4 protein). Transfected cells were then divided into two samples, one treated with CdSO₄ alone to induce expression of the GAL4-AML1c protein, and the other treated with CdSO₄ and PMA. As shown in Fig. 5D, PMA treatment of K562 cells stimulates the activity of wild type GAL4-AML1c by 5–6-fold. Introduction of the 4M mutations (serines 276, 293, and 303 and threonine 300 mutated to alanine, see Fig. 5C) abolished the PMA-induced activity of GAL4-AML1c but had little effect on basal activity (Fig. 5D). The introduction of further mutations in GAL4-AML1c-5M (the 4M mutations plus serine 462 mutated to alanine) and GAL4-AML1c-11M had little additional effect on activity.

In the GAL4-AML1c-5M (Ser Asp) protein, the 4M residues and serine 462 were mutated to aspartic acid. Without any treatment, these mutations to aspartic acid alone cause a 3–4-fold increase in GAL4-AML1c activity in untreated K562 cells (Fig. 5D), demonstrating that acidic charges at these positions are sufficient to activate transcription. As demonstrated (Fig. 5B) for full-length AML1c, PMA treatment further enhanced the transcriptional activity of the 5M (Ser Asp) protein. Overall, the effects of (S/T)P site mutations in the GAL4-AML1c protein confirm the results obtained by analysis of mutations in full-length AML1c. The serine and threonine residues mutated in AML1c-4M and GAL4-AML1c-4M drastically reduce activity when mutated to alanine and stimulate activity when mutated to aspartic acid. This clearly suggests that phosphorylation of these residues has a large role in the regulation of AML1c activity.

AML1c-4M and AML1c-11M Suppress the Activity of Several Different Promoters Containing AML1-binding Sites—The 4M (S/T)P site mutations clearly regulate the transcriptional activity of AML1c on the 4X-AML1 luciferase promoter and of GAL4-AML1c on a GAL4 luciferase promoter (Fig. 5). AML1-binding sites are found in the promoters of a number of genes involved in hematopoietic differentiation. We have selected four additional gene promoters for analysis with mutant AML1c proteins. The promoters used come from the T cell receptor (TCR-) gene, the myeloperoxidase gene, the macrophage colony-stimulating factor receptor gene, and the granulocyte-macrophage colony-stimulating factor gene. Each gene promoter has been inserted upstream of luciferase coding sequences to create a reporter plasmid, and these reporter plasmids were cotransfected into K562 cells with AML1c expression vectors (Fig. 6). The reporter plasmids were cotransfected with empty vector or vectors expressing wild type AML1c, AML1c-4M, or AML1c-11M.

View larger version (25K): [in this window] [in a new window]   FIG. 6. (S/T)P site mutations in AML1c inhibit the activity of the protein on a variety of promoters. K562 cells were transfected with 10 µg of the luciferase reporter plasmid indicated above each graph, 20 µg of empty vector (pcDNA3) or AML1c expression vector, and 0.25 µg of pCMV-Renilla-luciferase. The AML1c expression plasmids used are indicated below each graph. Approximately 6 h after transfection, cells were either treated with 200 nM PMA or left untreated (solid bars = untreated, and open bars = PMA). Sixteen to twenty four hours after transfection, cells were lysed for luciferase assays. Assays of luciferase from the 4XAML1 luciferase plasmid or other reporter plasmids (firefly luciferase) and of Renilla luciferase were carried out separately. The Renilla luciferase values were used to normalize the 4XAML-luciferase values. All experiments were repeated a minimum of three times, and the S.D. from the mean is shown.

The results shown in Fig. 6 suggest that specific phosphorylation sites on AML1c may be important for normal AML1c activity on some promoters but not on others. Because each promoter binds a unique combination of transcription factors, AML1c will be subject to a specific set of protein-protein interactions. Phosphorylation at a particular site on AML1c may promote some interactions, inhibit others, or have no effect at all.

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The phosphorylation of AML1c is clearly a complex process. The protein is phosphorylated at multiple sites that display different responses to PMA stimulation. Phosphorylation of four closely spaced serine and threonine residues (serines 276, 293, 303, and threonine 300) plays a key role in the regulation of AML1c activity. Unlike most other Ser-Pro or Thr-Pro sites in the AML1c activation domain, these four sites all exhibit increased phosphorylation in response to PMA treatment. Mutation of these four sites to alanine reduces AML1c transcriptional activity; mutation of the four sites to aspartic acid enhances transcriptional activity.

It is not yet clear whether each of these sites has a specific function or whether the sites act together, with the function of individual sites being somewhat redundant. Our experiments show that single mutation of a phosphorylation site or a double mutation out of four sites (either serines 276 and 293 or threonine 300 and serine 303) has little or no effect on transcriptional activation by AML1c. This suggests that all four sites may regulate the same process and that retention of at least two sites leaves AML1c functional.

Mutation of the other seven Ser-Pro/Thr-Pro sites in the AML1c activation domain, individually or in pairs, appears to have little effect on AML1c transcriptional activation.² However, mutation of all 11 AML1c Ser-Pro or Thr-Pro sites results in a protein with less transcriptional activity than the 4M protein, at least on some promoters. This suggests that the four PMA-induced Ser-Pro/Thr-Pro sites in the AML1c activation domain may be the strongest regulators of activity, but the remaining sites may have subtle effects on activity, perhaps through different mechanisms. We cannot rule out the possibility that the 11M mutant destroys the tertiary structure of the carboxyl terminus preventing any binding of transcriptional activators.

We find that mutation of five (S/T)P residues to aspartic acid converts AML1c to a constitutive activator of transcription. This finding again suggests the importance of these sites to the control of transcription by this protein. In addition, we find that PE further stimulates the activity of this protein even when the five sites are mutated. This result might be explained by our previous observation that PE treatment of leukemic cells can modulate other proteins involved in the transcription process, for example the activity of the TATA box-binding protein (39). Alternatively, it cannot be ruled out that PE treatment is also causing changes in the phosphorylation of other sites that enhance the effects of the major phosphorylation targets.

The phosphorylation pattern we have observed for AML1c appears to be different from those observed with other AML proteins. Previous studies on the AML1b protein (28) have identified only two phosphorylation sites, on AML1b serines 249 and 266. Phosphorylation of these sites was induced by overexpression of ERK and epidermal growth factor treatment of COS-7 cells or by interleukin-3 treatment of BAF3 cells. AML1b and AML1c are products of alternately spliced mRNAs from the AML1 gene and are identical except for 32 amino acids at the amino terminus. AML1b serines 249 and 266 are equivalent to AML1c serines 276 and 293, two of the residues we have identified as PMA-induced phosphorylation sites. It is unclear why AML1b and AML1c would have very different phosphorylation patterns; it is possible that the extent of phosphorylation at each site is cell type-specific or the extent of stimulation of the ERK pathway may regulate varying phosphorylation sites.

Phosphorylation sites have also been identified for the RUNX2/AML3 protein (40). RUNX2/AML3 shares extensive sequence homology with RUNX1/AML1. RUNX2/AML3 serines 14 and 451 were identified as major phosphorylation sites and serine 104 as a minor phosphorylation site when the protein was expressed in 293T, SAOS-2, or COS-7 cells. RUNX2/AML3 serine 451 corresponds to RUNX1/AML1c serine 424, which we identified as a phosphorylation site that does not respond to PMA in K562 cells. Mutation of RUNX2/AML3 serine 451 to alanine increased RUNX2/AML3 transcriptional activity, whereas mutation of this serine to glutamic acid had no effect (40). This suggested that phosphorylation of RUNX2/AML3 serine 451 suppressed activity. In contrast, mutation of RUNX1/AML1c serine 424 had little or no effect on transcriptional activity.² This difference may be either protein-specific or cell type-specific.

The two phosphorylation sites in the RUNX2/AML3 amino terminus, serines 14 and 104, correspond to RUNX1/AML1c threonine 41 and serine 94. RUNX1/AML1c has an additional Ser-Pro site at serine 48; in RUNX2/AML3 this serine has been replaced by glutamine. Mutation of RUNX2/AML3 serine 104 to glycine or glutamic acid reduced RUNX2/AML3 activity and appeared to destabilize the protein. Mutation of serine 104 to glutamic acid also appeared to inhibit the interaction between RUNX2/AML3 and its heterodimerization partner, CBF-, although mutation of serine 104 to glycine did not have this effect. It is therefore possible that phosphorylation of RUNX2/AML3 serine 104 inhibits the interaction between RUNX2/AML3 and CBF-, but it is also possible that the effects of mutations at serine 104 are conformational. We find that mutation of RUNX1/AML1c serine 94, comparable with RUNX2/AML3 serine 104, has little or no effect on RUNX1/AML1c activity.²

Mutation of the other RUNX2/AML3 amino-terminal phosphorylation site, serine 14, had no detectable effect on RUNX2/AML3 activity (40). Likewise, we find that mutation of RUNX1/AML1c threonine 41 and serine 48 eliminates phosphorylation of the amino terminus but has little effect on RUNX1/AML1c activity.² The functional significance of RUNX1/AML1c amino-terminal phosphorylation therefore remains unclear.

PE-induced differentiation of K562 and U937 cells has been a model for examining how small molecules might regulate protein kinases to inhibit the growth of leukemic cells. PE stimulates the mitogen-activated protein kinase family of enzymes and regulates the activity of a number of transcription factors, including c-JUN and ETS. Here we demonstrate that PE activation of the ERK pathway has profound effects on the activity of AML1. These findings shed light on how PE regulates genes that are essential for the control of hematopoietic differentiation.

	FOOTNOTES

 
^* This work was supported by National Institutes of Health Grant CA42533 (to A. S. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Present address: The Scripps Research Institute, 10550 North Torrey Pines Rd., La Jolla, CA 92037.

To whom correspondence should be addressed: Hollings Cancer Center, the Medical University of South Carolina, 86 Jonathan Lucas St., Charleston, SC 29425. Tel.: 843-792-8284; Fax: 843-792-9456; E-mail: Kraft{at}musc.edu.

¹ The abbreviations used are: PMA, phorbol 12-myristate 13-acetate; PE, phorbol ester; ERK, extracellular signal-regulated kinase; TCR, T cell receptor; CBF, core binding factor; PBS, phosphate-buffered saline; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase.

² Y. Zhang, J. R. Biggs, and A. S. Kraft, unpublished data.

	ACKNOWLEDGMENTS

 
We thank Scott W. Hiebert for the wild type AML1c expression plasmid, Yoram Groner for the TCR--luciferase reporter plasmid, and Alan D. Friedman for the 4X-AML-luciferase reporter plasmid.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Smithgall, T. E. (1998) Pharmacol. Rev. 50, 1–19[Abstract/Free Full Text]
2. Gonzalez, R., Ebbinghaus, S., Henthorn, T. K., Miller, D., and Kraft, A. S. (1999) Melanoma Res. 9, 599–606[Medline] [Order article via Infotrieve]
3. Lacaud, G. L., Gore, M., Kennedy, V., Kaouskoff, V., Kingsley, P., Hogan, C., Carlsson, L., Speck, N., Palis, J., and Keller, G. (2002) Blood 100, 458–466[Abstract/Free Full Text]
4. Okuda, T., Takeda, K., Fujita, Y., Nishimura, M., Yagyu, S., Yoshida, M., Akira, S., Downing, J. R., and Abe, T. (2000) Mol. Cell. Biol. 20, 319–328[Abstract/Free Full Text]
5. Zhang, Y. W., Bae, S. C., Huang, G., Fu, Y. X., Lu, J., Ahn, M. Y., Kanno, Y., Kanno, T., and Ito, Y. (1997) Mol. Cell. Biol. 17, 4133–4145[Abstract]
6. Nagata, T., and Werner, M. H. (2001) J. Mol. Biol. 308, 191–203[CrossRef][Medline] [Order article via Infotrieve]
7. Niki, M., Okada, H., Takano, H., Kuno, J., Tani, K., Hibino, H., Asano, S., Ito, Y., Satake, M., and Noda, T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 5697–5702[Abstract/Free Full Text]
8. Harada, H., Harada, Y., Tanaka, H., Kimura, A., and Inaba, T. (2003) Blood 101, 673–680[Abstract/Free Full Text]
9. Michaud, J., Wu, F., Osato, M., Cottles, G. M., Yanagida, M., Asou, N., Shigesda, K., Ito, Y., Benson, K. F., Raskind, W. H., Rossier, C., Antonarakis, S. E., Israels, S., McNicol, A., Weiss, H., Horwitz, M., and Scott, H. S. (2002) Blood 99, 1364–1372[Abstract/Free Full Text]
10. Cockerill, P. N., Osborne, C. S., Bert, A. G., and Grotto, R. J. M. (1996) Cell Growth & Differ. 7, 917–922[Abstract]
11. Kanno, T., Kanno, Y., Chen, L.-F., Ogawa, E., Kim, W.-Y., and Ito, Y. (1998) Mol. Cell. Biol. 18, 2444–2454[Abstract/Free Full Text]
12. Levanon, D., Goldstein, R. E., Bernstein, Y., Tang, H., Goldenberg, D., Stifani, S., Paroush, Z., and Groner, Y. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11590–11595[Abstract/Free Full Text]
13. McLarren, K. W., Lo, R., Grbacec, D., Thirunavukkarasu, K., Karsenty, G., and Stifani, S. (2000) J. Biol. Chem. 275, 530–538[Abstract/Free Full Text]
14. Westendorf, J. J., Yamamoto, C. M., Lenny, N., Downing, J. R., Selsted, M. E., and Hiebert, S. W. (1998) Mol. Cell. Biol. 18, 322–333[Abstract/Free Full Text]
15. Tonks, A., Pearn, L., Tonks, A. J., Pearce, L., Hoy, T., Phillips, S., Fisher, J., Downing, J. R., Burnett, A. K., and Darley, R. L. (2003) Blood 101, 624–632[Abstract/Free Full Text]
16. Zhang, D.-E., Hetherington, C. J., Meyers, S., Rhoades, K. L. Larson, C. J., Chen, H. M., Hiebert, S. W., and Tenen, D. G. (1996) Mol. Cell. Biol. 16, 1231–1240[Abstract]
17. Britos-Bray, M., and Friedman, A. D. (1997) Mol. Cell. Biol. 17, 5127–5135[Abstract]
18. Nuchprayoon, I., Meyers, S., Scott, L. M., Suzow, J., Hiebert, S., and Friedman, A. D. (1994) Mol. Cell. Biol. 14, 5558–5568[Abstract/Free Full Text]
19. Burel, S. A., Harakawa, N., Zhou, L., Pabst, T., Tenen, D. G., and Zhang, D.-R. (2001) Mol. Cell. Biol. 21, 5577–5590[Abstract/Free Full Text]
20. Sakakura, C., Yamaguchi-Iwai, Y., Satake, M., Bae, S. C., Takahashi, A., Ogawa, E., Hagiwara, A., Takahashi, T., Murakami, A., and Makino, K. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11723–11727[Abstract/Free Full Text]
21. Kitabayashi, I., Aikawa, Y., Nguyen, L. A., Yokoyama, A., and Ohki, M. (2001) EMBO J. 20, 7184–7196[CrossRef][Medline] [Order article via Infotrieve]
22. Kitabayashi, I., Yokoyama, A., Shimizu, K., and Ohki, M. (1998) EMBO J. 17, 2994–3004[CrossRef][Medline] [Order article via Infotrieve]
23. Pelletier, N., Champagne, N., Stifani, S., and Yang, X.-J. (2002) 21, 2729–2740
24. Yagi, R., Chen, L.-F., Shigesada, K., Murakami, Y., and Ito, Y. (1999) EMBO J. 18, 2551–2562[CrossRef][Medline] [Order article via Infotrieve]
25. Lutterbach, B., Westendorf, J. J., Linggi, B., Isaac, S., Seto, E., and Hiebert, S. W. (2000) J. Biol. Chem. 275, 651–656[Abstract/Free Full Text]
26. Petrovick, M. S., Hiebert, S. W., Friedman, A. D., Hetherington, C. J., Tenen, D. G., and Zhang, D.-E. (1998) Mol. Cell. Biol. 18, 3915–3925[Abstract/Free Full Text]
27. Zeng, C., McNeil, S., Pockwinse, S., Nickerson, J., Shopland, L., Lawrence, J. B., Penman, S., Hiebert, S., Lian, J. B., van Wijnen, A. J., Stein, J. L., and Stein, G. S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1585–1589[Abstract/Free Full Text]
28. Tanaka, T., Kurokawa, M., Ueki, K., Tanaka, K., Imai, Y., Mitani, K., Sagata, N., Yazaki, Y., Shibata, Y., Kadowaki, T., and Hirai, H. (1996) Mol. Cell. Biol. 16, 3967–3979[Abstract]
29. Franklin, C. C., and Kraft, A. S. (1997) J. Biol. Chem. 272, 16917–16923[Abstract/Free Full Text]
30. Franklin, C. C., and Kraft, A. S. (1995) Oncogene 11, 2365–2374[Medline] [Order article via Infotrieve]
31. Kim, K. W., Kim, S.-H., Lee, E. Y., Kim, N. D., Kang, H. S., Kim, H. D., Chung, B.-S., and Kang, C.-D. (2001) J. Biol. Chem. 276, 13186–13191[Abstract/Free Full Text]
32. Wotton, D., Prosser, H. M., and Owen, M. J. (1993) Leukemia (Baltimore) 7, Suppl. 2, S55–S60
33. Cirillo, G., Casalino, L., Vallone, D., Caracciolo, A., De Cesare, D., and Verde, P. (1999) Mol. Cell. Biol. 19, 6240–6252[Abstract/Free Full Text]
34. Carey, J. O., Posekany, K. J., deVente, J. E., Pettit, G. R., and Ways, D. K. (1996) Blood 87, 4316–4324[Abstract/Free Full Text]
35. Murakami, K., Mavrothalassitis, G., Bhat, N. K., Fisher, R. J., and Papas, T. S. (1993) Oncogene 8, 1559–1566[Medline] [Order article via Infotrieve]
36. Biggs, J. R., and Kraft, A. S. (1999) J. Biol. Chem. 274, 36987–36994[Abstract/Free Full Text]
37. Cao, W., Adya, N., Britos-Bray, M., Liu, P. P., and Friedman, A. D. (1998) J. Biol. Chem. 273, 31534–31540[Abstract/Free Full Text]
38. Whalen, A. M., Galasinski, S. C., Shapiro, P. S., Nahreini, T. S., and Ahn, N. G. (1997) Mol. Cell. Biol. 17, 1947–1958[Abstract]
39. Biggs, J. R., Ahn, N. G., and Kraft, A. S. (1998) Cell Growth & Differ. 9, 667–676[Abstract]
40. Wee, H.-J., Huang, G., Shigesaga, K., and Ito, Y. (2002) EMBO Rep. 3, 967–974[CrossRef][Medline] [Order article via Infotrieve]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				L. Zhang, F. B. Fried, H. Guo, and A. D. Friedman Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation Blood, February 1, 2008; 111(3): 1193 - 1200. [Abstract] [Full Text] [PDF]

				J. R. Biggs, L. F. Peterson, Y. Zhang, A. S. Kraft, and D.-E. Zhang AML1/RUNX1 Phosphorylation by Cyclin-Dependent Kinases Regulates the Degradation of AML1/RUNX1 by the Anaphase-Promoting Complex Mol. Cell. Biol., October 15, 2006; 26(20): 7420 - 7429. [Abstract] [Full Text] [PDF]

				Z. Yuan, A. Tie, M. Tarnopolsky, and M. Bakovic Genomic organization, promoter activity, and expression of the human choline transporter-like protein 1 Physiol Genomics, September 14, 2006; 26(1): 76 - 90. [Abstract] [Full Text] [PDF]

				V. Hamelin, C. Letourneux, P.-H. Romeo, F. Porteu, and M. Gaudry Thrombopoietin regulates IEX-1 gene expression through ERK-induced AML1 phosphorylation Blood, April 15, 2006; 107(8): 3106 - 3113. [Abstract] [Full Text] [PDF]

				J. E. Phillips, C. A. Gersbach, A. M. Wojtowicz, and A. J. Garcia Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation J. Cell Sci., February 1, 2006; 119(3): 581 - 591. [Abstract] [Full Text] [PDF]

				S. Wang, Y. Zhang, J. R. Biggs, D.-E. Zhang, and A. S. Kraft Phosphorylation of AML1 (RUNX1) Controls Transcription, Nuclear Localization, and Is Regulated during DNA Damage. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 2712 - 2712. [Abstract]

				J. R. Biggs, Y. Zhang, L. F. Peterson, M. Garcia, D.-E. Zhang, and A. S. Kraft Phosphorylation of AML1/RUNX1 Regulates Its Degradation and Nuclear Matrix Association Mol. Cancer Res., July 1, 2005; 3(7): 391 - 401. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 279/51/53116    most recent M405502200v1